Molecular Properties
| Parameter | Value |
|---|---|
| Chemical Name | Growth Hormone Releasing Peptide-2 / Pralmorelin |
| Amino Acid Sequence | D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂ |
| Molecular Formula | C₄₅H₅₅N₉O₆ |
| Molecular Weight | 817.97 g/mol |
| CAS Number | 158861-67-7 |
| Sequence Length | 6 amino acids (synthetic hexapeptide with D-amino acids) |
| Receptor Target | Growth Hormone Secretagogue Receptor 1a (GHS-R1a) / Ghrelin receptor |
Physical Properties
| Property | Specification |
|---|---|
| Appearance | White to off-white lyophilized powder |
| Solubility | Soluble in water or aqueous buffer at ≥1 mg/mL; pH 5.5-7.5 |
| pH (1% solution) | 5.5 - 7.5 |
| Hygroscopicity | Low to moderate; standard desiccated storage |
| Solution Stability | Stable at 4°C for 10-14 days; D-amino acids enhance stability |
Analytical Specifications
| Test | Specification |
|---|---|
| HPLC Purity | ≥98.0% |
| Mass Spectrometry | Confirmed [M+H]⁺ = 817.97 ± 0.5 Da |
| Peptide Content | ≥95% (by amino acid analysis) |
| Endotoxin Level | <1.0 EU/mg |
| Acetate Content | ≤5% |
| TFA Content | ≤0.1% |
| Water Content | ≤6% (Karl Fischer) |
Storage Parameters
| Condition | Specification |
|---|---|
| Lyophilized Storage | -20°C, desiccated |
| Lyophilized Shelf Life | 24-36 months when stored properly |
| Reconstituted Storage | 2-8°C for up to 14 days; -20°C for up to 3 months |
| Analytical Stock Preparation | Dissolve in sterile water or aqueous buffer with gentle vortexing for 30 seconds |
| Freeze-Thaw Cycles | Tolerates up to 5 cycles; D-amino acids provide stability |
| Light Sensitivity | Low; standard laboratory storage acceptable |
In Vitro & Preclinical Model Concentrations
| Experimental Model | Published Concentration / Regimen | Exposure Schedule | Administration Context |
|---|---|---|---|
| In Vitro Pituitary Cell Assays | 10-1000 nM | Acute stimulation (30 min to 2 hours) | Culture media |
| Small Animal Models (Rodent) | 50-500 μg/kg | 1-3x daily | SC or IV in rodent models |
| GH Secretion Studies (Rodent) | 100-300 μg/kg | Single bolus or repeated over 7-28 days | SC in rodent models |
| Appetite/Ghrelin Research (Rodent) | 200-600 μg/kg | 30-60 min before measurements | SC or IP in rodent models |
Note: Concentrations and animal regimens summarized above are for research reference only. GHRP-2 is intended for laboratory research and mimics ghrelin action at the GHS-R1a receptor.
Key Research Studies
| Year | Study Focus | Key Findings |
|---|---|---|
| 1995 | Discovery and characterization of GHS-R | GHRP-2 identified as potent synthetic ligand for orphan GPCR (later named GHS-R1a); demonstrated EC₅₀ of 0.1-1 nM for GH release; 10-100x more potent than GHRH in vitro |
| 1999 | Synergy with GHRH | Combined GHRP-2 + GHRH administration produced synergistic GH response (5-10x vs either alone); demonstrated distinct receptor mechanisms and complementary signaling pathways |
| 2006 | Appetite stimulation and orexigenic effects | GHRP-2 (300 μg/kg SC) increased food intake by 40-60% within 2 hours in animal models; activated NPY/AgRP neurons in arcuate nucleus; effects blocked by GHS-R1a antagonists |
| 2012 | Cardioprotective and anti-inflammatory effects | GHRP-2 treatment (200 μg/kg twice daily) reduced infarct size by 30-40% in cardiac ischemia models; decreased inflammatory markers (IL-6, TNF-α); GHS-R1a-dependent and independent mechanisms identified |
Mechanism of Action
| Biological Pathway | Description |
|---|---|
| GHS-R1a Activation | Binds ghrelin receptor (GHS-R1a), Gq-coupled GPCR; high affinity (Kd ~0.5-5 nM); expressed in pituitary, hypothalamus, heart, adipose |
| GH Secretion | Activates pituitary somatotrophs → PLC/PKC pathway → Ca²⁺ mobilization → GH release; peak GH at 15-30 minutes post-stimulus |
| Hypothalamic Effects | Stimulates arcuate NPY/AgRP neurons → orexigenic response; modulates GHRH neuron activity; amplifies endogenous GH pulses |
| Peripheral Actions | Cardioprotection via GHS-R1a-dependent and independent mechanisms; anti-inflammatory effects; modulation of adipocyte function |
| Half-Life | 20-30 minutes (IV/SC); D-amino acids provide resistance to peptidases vs natural peptides |
Comparative Analysis: GHRP Family
| Compound | MW (Da) | GH Potency | Appetite Effect | Cortisol/Prolactin |
|---|---|---|---|---|
| GHRP-2 | 817.97 | High (EC₅₀ ~0.1-1 nM) | Strong (+40-60%) | Moderate increase |
| GHRP-6 | 872.44 | High (EC₅₀ ~0.2-2 nM) | Very strong (+60-100%) | Moderate increase |
| Hexarelin | 887.04 | Very high (EC₅₀ ~0.05-0.5 nM) | Moderate (+20-40%) | Strong increase |
| Ipamorelin | 711.85 | Moderate (EC₅₀ ~1-10 nM) | Minimal | No increase (selective) |
Quality Control Parameters
| Test Method | Acceptance Criteria |
|---|---|
| Appearance (visual) | White to off-white powder; no aggregation |
| Chiral Purity | D-amino acids at positions 1, 2, 5 confirmed; >98% correct stereochemistry |
| RP-HPLC (purity) | Main peak ≥98.0%; no single impurity >0.5% |
| ESI-MS (identity) | [M+H]⁺ = 817.97 ± 0.5 Da confirmed |
| Biological Activity | ≥85% potency vs reference in GH release assay |
Structure-Activity Relationship
| Position | Amino Acid | Structural Role |
|---|---|---|
| 1 | D-Ala | N-terminal stability; prevents aminopeptidase degradation |
| 2 | D-2-Nal (D-2-naphthylalanine) | Critical for receptor binding; aromatic interaction with GHS-R1a |
| 3 | L-Ala | Conformational spacer |
| 4 | L-Trp | Essential for activity; indole ring interactions |
| 5 | D-Phe | Receptor selectivity; D-configuration critical |
| 6 | L-Lys-NH₂ | C-terminal; positive charge; amidation essential |
Reported Biological Effects
| Effect Category | Observed Changes | Timeframe |
|---|---|---|
| GH Secretion | Peak GH increase 5-20x baseline; occurs 15-30 min post-stimulus; duration 1-2 hours | Acute (minutes to hours) |
| IGF-1 Levels | Increased 30-50% with repeated administration in animal models; cumulative effect over 1-2 weeks | 7-14 days |
| Appetite | Increased food intake 40-60% in rodent models; peak effect 1-3 hours post-stimulus | Acute (1-4 hours) |
| Body Composition (Preclinical) | Increased lean mass 2-5%; modest fat reduction in chronic animal studies | 4-8 weeks |
Regulatory & Compounding Status (April 2026)
On FDA’s page on bulk drug substances used in compounding, current as of April 22, 2026, GHRP-2 is listed in Category 2 under 503B (bulk drug substances that raise significant safety risks in compounding). Pralmorelin hydrochloride has been used in Japan as a single-dose diagnostic agent for growth hormone deficiency, but GHRP-2 is not approved by the U.S. FDA for human therapeutic use. This monograph is intended strictly for laboratory research.
External References
- Bowers CY, et al. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-45. https://pubmed.ncbi.nlm.nih.gov/6143887/
- Smith RG, et al. Peptidomimetic regulation of growth hormone secretion. Endocr Rev. 1997;18(5):621-45. https://academic.oup.com/edrv/article/18/5/621/2548680
- National Center for Biotechnology Information. PubChem Compound Summary for GHRP-2. https://pubchem.ncbi.nlm.nih.gov/compound/GHRP-2
